Britannia Biological LLP is a WHO GMP certified company and has ISO 9001:2008 certification
Right from its inception Britannia Biological LLP objective remained to provide drugs of the highest quality and purity for the common man that is zealously persuade till date. ‘Excellence in quality’ is a commitment and the entire staff is dedicated towards this common goal. The quality did not start but was there from the beginning of the unit when the FDA, India, granted the GMP certificate. The regulatory body in India has the most stringent laws comparable to any international body and is fairly similar to the US FDA. As a result from the continued efforts to upgrade the existing facility and technology with much hard work, the company’s major achievement was when it was granted the WHO GMP certificate for 99 products. We proud our self to be among the best generic and branded generics companies in India for the quality product we produce.
In keeping with the needs of the time, the venture is totally eco and environment friendly. The manufacturing process is being disposed off as per the industrial norms and guidelines. Strict compliance to the rules and regulations set forth by the pollution control board are being adhered to. Britannia Biological LLP looks for the stronger support of its people to adhere to cGMP requirements. Britannia Biological LLP is continuously upgrading its facility not only in quality but also its management & administration control.
The lifeline of the company and strength to recon with, we believe that “He who has the most stringent quality control will have the best product”. The company has a self-sufficient laboratory in place and have some most dedicated personnel’s who are highly motivated to lead this organization. Apart from the Pharmacopoeia requirements the laboratory is equipped to conduct various tests that are required to make a quality product. Capability to identify the impurities and to study the degradation of the products helps to improve the product quality and improves the general understanding of the products.
Britannia Biological LLP has ever since strived to improve its existing facility by carrying out regular inspection and updating of technology for its products and processes and thus adhere to cGMP. To ensure that the cGMP standards are met and products comply with international quality standards, quality control measures having been imbibed at various stages of productions-from approval of raw materials to goods in-process as well as monitoring of the manufacturing process and extends up-to checking of finished goods. Quality assurance in the production is adhered by strict in-process controls and by validation and optimization of the process to improve quality and production.
CAPA: Corrective and Preventive actions
The company has in place a complete written program under CAPA and the procedure is well defined
Britannia Biological LLP under CAPA is analyzing processes, work operations, quality audit reports, quality records, service records complaints, returned product and other sources of quality data to identify existing and potential causes of nonconforming product and other quality problems. Appropriate statistical methodology is employed where necessary to detect recurring quality problems.
Investigation is done for the cause of nonconformities relating to product, processes and the quality system.
Identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems.
Verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished product.
Recording changes in methods and procedures needed to correct and prevent identified quality problems.
Ensuring that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product for the prevention of such problems.
Submitting relevant information on identified quality problems, as well as corrective and preventive actions, for management review.
Britannia Biological LLP was established as one of the leading PCD pharma companies to meet the most basic needs for effective and affordable treatment. We have been successful because we have always been working to meet the need for basic healthcare for promoting human health. Our PCD Pharma Company is always striving to add key new products to the market every year. Our product line is developed through:
IN-HOUSE PRODUCT DEVELOPMENT
WHAT OUR DISTRIBUTORS GET
Britannia Biological LLP offers franchise marketing distributorship for your region through monopoly rights. We are the leaders offering the highest quality of widest range of products. As a leading PCD Pharma Company in India, we offer promotional methods including visual aids with complete detailing, appealing catch cover, product cards, leave behinds, glossary, order books, visiting cards, doctor’s pad, MR bag, gift articles and much more. The latest promotional outputs are available free of cost.
WHY WE ARE DIFFERENT FROM OTHER PCD PHARMA COMPANIES
We count on the power of caring in the progress of our business, which has helped us become one of the top PCD pharma company India. Progressive Life Care stands out from other pharma companies in Gujarat because we are always innovating, creating and improving to remain as efficient as possible in all the areas where our products are required.
Contact us for Unique PCD Pharmaceutical Franchise Company in India
Research & Development
There are strong R&D facilities that are contemplated and designed for both drug discovery and development. In addition to it, there are number of scientists, who are engaged in several path-breaking researches.
If you have a need for a unique product, Britanna R&D will develop it for you.
Our Unique R&D Strengths:
- Top notch, highly qualified team with burning desire for new product development
● State of the art equipment and best resources
● Ability to turn around products in minimal time frame
On Going R&D
For Britannia Biological LLP, Research and Development have always been a major component. Spectrums of research are carried out in Britannia Biological LLP, ranging from development of new applications for existing products to upgrading formulation efficiency and improving drug delivery systems. Our independent Research and Development department staffed by well-qualified chemists are involved in a range of research efforts.
Britannia Biological LLP has a Microbiological Laboratory, outfitted and well equipped with the current and high-tech facilities, to
● Conduct routine and in-depth microbiological testing
● Establish product protocols and
● Validate sterilization processes.
In-depth tests are performed to assess raw materials, bulk and finished formulations. In addition, there is on-going microbiological monitoring of working procedures in process areas and microbiological analysis on products.
Research and Development Laboratory developed by Britannia Biological LLP will further explore promising opportunities for medical advances. The new laboratory’s service will also be extended to offer research on a contract basis.
R & D Capabilities
R&D is a major strength of our company Britannia Biological LLP. We have a team of over 50 experienced scientists specializing in Formulation Development, Analytical development and Conducting Stability Studies.
Our dedicated research team is committed to developing a range of formulation and products as per customer specifications and for positively impacting health and well-being.
Key R&D areas
Our research effort drives our vision of becoming a respected, profitable and integrated global pharmaceuticals company. A focused effort in defined areas and a lasting interest in new technology are the key features of our efforts.
Our R&D centre is active across almost all facets of the business, which includes:
- Developing generic products and pharmaceutical formulations
- Identifying niche areas (such as Cardiovascular diseases, Diabetes, and Neuroscience), for product development
- Post Patent filing for regulated and emerging markets
- Collaborating with our partners for developing drugs, which are going Off Patent
These activities are synchronized to provide us a competitive advantage in the new patent regime. In the near future, the company has ambitious plans for expanding its research capabilities for focused R&D activities, in the shortest time and at the lowest cost.
- A full-fledged R&D Centre equipped with the most modern research infrastructure
- A team of distinguished scientists who can leverage their skills to develop products as per emerging business opportunities
- An ability to formulate and market drugs in the shortest possible lead time
- The company plans to enhance its product portfolio with the addition of 12-13 products every year
- Offering CRAMS for existing and emerging markets is envisaged as one of the major driver and revenue earner for the company